Navigation Links
Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
Date:7/7/2010

BETHESDA, M.D., July 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO), developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors.  The funding included $1.75 million in purchases of restricted common stock of the Company (the "Common Stock") by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.  The Company also continued to make progress on restructuring of its balance sheet, through debt conversions and extensions with its largest debt holders.  The new investment by SDS Capital was part of a larger restructuring transaction with SDS.

The $1.75 million in purchases of Common Stock by private investors were made at a price of seventy-five cents ($0.75) per share, with ten percent (10%) warrant coverage.

The restructuring transaction with SDS Capital was undertaken pursuant to a Conversion and Extension Agreement, which included the conversion or extension of all outstanding debt held by SDS, as well as new investment of $250,000 by SDS.  Prior to this Agreement, SDS was the second largest holder of investment debt of the Company.

As previously reported, the Company already entered into an agreement with the Al Rajhi Group in March, 2010, for the extension of all outstanding debt held by Al Rajhi. The Al Rajhi Group is the largest holder of investment debt of the Company.

The Company also entered into a Securities Purchase Agreement with Ms. Linda F. Powers, the Chair of the Company's Board, for the purchase of restricted Common Stock.  Ms. Powers purchased $650,000 of restricted Common Stock at a price per share of seventy-five cents ($0.75), and ten percent (10%) warrant coverage. Accordingly, Ms. Powers purchased 866,667 shares of the Company's restricted Common Stock and warrants for 86,667 shares of Common Stock.  Prior to this purchase, Ms. Powers sold 750,000 shares of her Common Stock.

As part of the Company's ongoing strengthening of its balance sheet, the Company is using the proceeds of the sale of stock to Ms. Powers to pay down certain outstanding trade payables.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company has two broad platform technologies:  dendritic cell-based vaccines and therapeutic antibodies.  The Company is focusing on development of its dendritic cell vaccines.  The Company's lead clinical trial is a 240 patient double blind, randomized, placebo controlled Phase II trial in GBM.  The trial remains open but is not currently enrolling patients.  As part of the debt restructuring and ongoing fundraising activities, the Company expects to resume enrollment in this GBM trial later in the summer.  The Company also received clearance from the FDA some time ago for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and uncertainties about whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
2. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
3. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
4. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
5. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
6. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
7. Oncothyreon to present at Invest Northwest 2009
8. Sirius Genomics to Present at Invest Northwest Conference
9. Northwest Biotherapeutics Secures $700,000 Equity Financing
10. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
11. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):